This new treatment combination is being made available via the CDF on the NHS for the first time following a recommendation by the National Institute of Health and Care Excellence (NICE). This decision follows an earlier draft negative decision by NICE in July last year. Daratumumab, which is produced by the pharmaceutical company Janssen, belongs to a…
DetailsFinding answers to discover a cure for myeloma is one of our main objectives at Myeloma UK. We are committed to achieving this with the help of supporters such as Alison Goldberg and Sara Phillips, who are trustees of The Joyce and Norman Freed Charitable Trust, which they established in 2016 to help fund projects…
DetailsMyeloma UK is helping to Make Blood Cancer Visible in September. The campaign, in partnership with Janssen Oncology and eight patient organisations, marks Blood Cancer Awareness Month. It will feature a public art installation, which will help visitors to understand the experiences of people affected by blood cancer. The installation is made up of…
DetailsThis month Myeloma UK published a new research report recommending that researchers, the NHS and healthcare professionals work together to improve the way that patient reported outcome measures (PROMs) are utilised in myeloma research. PROMs are questionnaires that are completed by patients and are often used either in a clinical trial setting to measure the impact of a…
DetailsResults from a retrospective study have shown that prophylactic treatment with doxycycline and ciprofloxacin reduces the incidence of infection in myeloma patients following an autologous stem cell transplant (ASCT), when compared to treatment with ciprofloxacin alone. Published in Supportive Cancer Care, the results show that 53% of patients receiving ciprofloxacin alone developed neutropenic fever compared…
DetailsResults from a Phase II study, recently published in Leukaemia, show that the oral combination of ixazomib (Ninlaro®), pomalidomide (Imnovid®) and dexamethasone is effective in relapsed and refractory myeloma patients. All patients in this study were refractory to lenalidomide (Revlimid®). 48% of patients who received the recommended dose of ixazomib (4mg) achieved a partial response or…
DetailsPublished in the Journal of Clinical Oncology, results from the Phase II trial, MM-013 show that pomalidomide (Imnovid®) in combination with low-dose dexamethasone is effective in relapsed and refractory patients with renal impairment. There were 3 cohorts in this trial; patients with moderate renal impairment (A), severe renal impairment (B) and severe impairment requiring haemodialysis…
DetailsThe results from the Phase III ALCYONE trial have recently been published in The New England Journal of Medicine. The study compared daratumumab (Darzalex®) in combination with bortezomib (Velcade®), melphalan and prednisone (VMP) to VMP alone in newly diagnosed myeloma patients, ineligible for a stem cell transplant. The results show that the 18-month progression-free survival…
DetailsCelgene has announced that its Phase III trial, OPTIMISMM, has achieved its primary endpoint of improving progression-free survival (PFS) in patients with relapsed or refractory myeloma. The study compared pomalidomide (Imnovid®) in combination with bortezomib (Velcade®) and low-dose dexamethasone to bortezomib and low-dose dexamethasone in myeloma patients who had received 1 – 3 prior treatments,…
DetailsResults from the Phase III ASPIRE trial show that carfilzomib (Kyprolis®) in combination with lenalidomide (Revlimid®) and dexamethasone has a significant overall survival (OS) benefit in relapsed and refractory myeloma patients. Recently published in the Journal of Clinical Oncology, the results demonstrate that patients receiving carfilzomib, lenalidomide and dexamethasone had a median OS of 48.3…
Details
